Summary Background In September, 2008, the European Acute Stroke Study III (ECASS III)
randomised trial and the Safe Implementation of Treatment in Stroke-International Stroke …

Background Intravenous alteplase is approved for use within 3 h of ischaemic stroke onset,
although a meta-analysis of randomised controlled trials suggests treatment benefit up to 4 …

Background Few data are available from randomised trials about the effect of thrombolysis
with alteplase on long-term functional outcome in patients who have had acute ischaemic …

Summary Background In the European Cooperative Acute Stroke Study III (ECASS III),
alteplase administered 3· 0–4· 5 h after the onset of stroke symptoms resulted in a significant …

Background Alteplase is effective for treatment of acute ischaemic stroke but debate
continues about its use after longer times since stroke onset, in older patients, and among …

Background: Extending the therapeutic window for thrombolysis is an important strategy in
maximizing the proportion of patients treated. ECASS III examined a 3–4.5-hour window and …

Background The aim of the Safe Implementation of Thrombolysis in Stroke-Monitoring Study
(SITS-MOST) was to assess the safety and efficacy of intravenous alteplase as thrombolytic …

Background Thrombolysis for acute ischaemic stroke has been investigated in several
clinical trials, with variable results. We have assessed the safety and efficacy of intravenous …

The multinational Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-
MOSTS), in today's Lancet, is the largest observational study of intravenous alteplase in …

Background Intravenous thrombolysis with alteplase is the only approved treatment for acute
ischemic stroke, but its efficacy and safety when administered more than 3 hours after the …